AI specialist Recursion says lead drug is safe, but efficacy less clear

BioPharma Dive September 3, 2024
Ned Pagliarulo

Results from a Phase 2 study of people with a neurovascular condition showed a “trend” toward reduced brain lesion volume.

Dive Brief:

• Recursion Pharmaceuticals on Tuesday said results from a mid-stage trial showed its lead experimental drug to be safe, the first readout in a series of important data disclosures for the AI drug discovery specialist.
• But the summary findings Recursion announced provide little indication of whether the drug, a treatment for a potentially dangerous kind of vascular malformation in the brain, might be effective. MRI scans of the brains of study participants given the highest dose showed a “trend” toward smaller lesions, Recursion said.
• Shares in Recursion fell by double digits Tuesday morning. The Salt Lake City-based company...

Today's Sponsors

Today's Sponsor